Journal
JOURNAL OF MOLECULAR NEUROSCIENCE
Volume 45, Issue 3, Pages 467-472Publisher
HUMANA PRESS INC
DOI: 10.1007/s12031-011-9540-4
Keywords
Tau; Alzheimer's; Neurodegeneration; Neuroprotection; Solubility
Categories
Funding
- NIA NIH HHS [R00 AG031291] Funding Source: Medline
- NINDS NIH HHS [R01 NS073899] Funding Source: Medline
Ask authors/readers for more resources
Impaired nutrient delivery to the brain due to decreased blood flow contributes to cognitive decline and dementia in Alzheimer's disease (AD). Considering this, many studies have suggested that neuroprotective agents like those used in stroke could prevent AD onset or progression by promoting cell survival. However, research in the past decade suggests that the culprit behind the cognitive loss in AD models is actually the soluble tau accumulating inside of surviving neurons. In fact, tau reductions improve cognition in mouse models of AD, even those that only deposit amyloid plaques. There is emerging evidence that neuroprotection alone in these AD models may be insufficient to restore neuron function and cognition. Only when soluble tau is reduced on a neuroprotective background could memory be rescued. Thus, once a neuron begins to accumulate tau, it may survive in a malfunctioning capacity, leading to impaired electrical signaling and memory formation in the brain. These data imply that multiple drugs may be necessary to ameliorate the different disease components. In fact, strategies to preserve neurons without affecting the soluble protein burden within neurons may accelerate the disease course.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available